BioXcel Therapeutics

BTAIPhase 3

BioXcel Therapeutics utilizes its proprietary AI platform to identify and develop new therapeutic applications for existing drugs, focusing on high-need neuropsychiatric and immuno-oncology indications. The company achieved its first commercial approval with IGALMI and is actively expanding its pipeline, including promising Phase 2 results for BXCL501 in opioid withdrawal. Despite commercial challenges, BioXcel continues to pursue strategic financing and clinical development to address significant unmet medical needs.

Market Cap

$36.8M

Focus

Drug DeliverySmall Molecules

BTAI · Stock Price

USD 1.51349.85 (-99.57%)

Historical price data

AI Company Overview

Technology Platform

Proprietary artificial intelligence platform used to mine biomedical data and identify novel therapeutic applications for existing drugs, accelerating development in neuroscience and immuno-oncology.

Pipeline Snapshot

18 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
Dexmedetomidine + Lorazepam 2 MG/ML	Schizophrenia Agitation	Approved
Sublingual film containing Igalmi	Bipolar Disorder	Approved
Sublingual film containing Dexmedetomidine (BXCL501) + Placebo Film	Agitation Associated With Bipolar Disorder	Phase 3
BXCL501 + Matching Placebo	Agitation	Phase 3
BXCL501 + Matching Placebo	Agitation,Psychomotor	Phase 3

Funding History

Total raised: $190M

PIPE$100MUndisclosedFeb 15, 2021

IPO$75MUndisclosedJun 15, 2018

Series A$15MKohlberg Kravis RobertsMay 15, 2017

Opportunities

Significant opportunity exists in expanding the label for BXCL501 into opioid withdrawal, a major unmet need amid the ongoing opioid crisis.

Successful commercialization of IGALMI in hospital and emergency settings could establish a valuable franchise in acute neuropsychiatric care.

The AI platform offers potential for discovering additional pipeline candidates efficiently.

Risk Factors

Key risks include the challenge of commercializing IGALMI against established injectable competitors, ongoing financial losses requiring dilutive financing, and clinical trial risks for pipeline programs.

The company's low market capitalization limits financial flexibility.

Competitive Landscape

Competes in acute agitation with generic injectable antipsychotics/benzodiazepines and other emerging therapies. In opioid withdrawal, faces competition from opioid-based medications (buprenorphine) and supportive care. Differentiation lies in novel mechanisms (alpha-2a agonism) and non-invasive formulations (sublingual film).